Show simple item record

dc.creatorHayakawa, Takaoen
dc.date.accessioned2011-07-12T18:38:51Zen
dc.date.available2011-07-12T18:38:51Zen
dc.date.created1987en
dc.date.issued1987en
dc.identifier.bibliographicCitationProgress in Clinical and Biological Research 1987; 235: 15-29en
dc.identifier.urihttp://hdl.handle.net/10822/540454en
dc.formatArticleen
dc.languageengen
dc.source70289en
dc.subjectDNAen
dc.subjectDrugsen
dc.subjectGovernmenten
dc.subjectTechnologyen
dc.subject.classificationDrugs and Drug Industryen
dc.subject.classificationBiohazards of Genetic Researchen
dc.titleSome Aspects of the Preclinical Safety of Drugs Produced by Recombinant DNA Technology: Japanese Government Regulatory Positionen
dc.provenanceDigital citation created by the Bioethics Research Library, Georgetown University, for the National Information Resource on Ethics and Human Genetics, a project funded by the United States National Human Genome Research Instituteen
dc.provenanceDigital citation migrated from OpenText Livelink Discovery Server database named GenETHX to DSpace collection GenETHX hosted by Georgetown Universityen


This item appears in the following Collection(s)

Show simple item record


Georgetown University Seal
©2009—2022 Bioethics Research Library
Box 571212 Washington DC 20057-1212
202.687.3885